Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO
Volume: Volume 16, Pages: 1755 - 1770
Published: Jun 1, 2021
Abstract
Background: A pre-specified meta-analysis of individual patient data from the 52-week METREX and METREO trials, which investigated mepolizumab for chronic obstructive pulmonary disease (COPD) in patients with blood eosinophil counts ≥ 150 cells/μL (screening) or ≥ 300 cells/μL (prior year) and frequent exacerbations, enables more robust characterization of mepolizumab efficacy in COPD and exploration of the relationship between blood eosinophil...
Paper Details
Title
Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO
Published Date
Jun 1, 2021
Volume
Volume 16
Pages
1755 - 1770
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History